Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
METalmark
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- NCT05488314 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on METalmark (amivantamab plus capmatinib in unresectable metastatic non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on METalmark so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 1 YouTube video | |
| 1 podcast episode | |
| 1 post on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Capmatinib; Amivantamab
- Arms
- Phase 1 (Combination Dose Selection) · Experimental
- Phase 2 (Dose Expansion) · Experimental
- Enrollment
- 57
- Primary outcomes
- Phase 1: Number of Participants with Adverse events (AEs) by Severity
- Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs)
- Phase 2: Objective Response Rate
- Sponsor
- Janssen Research & Development, LLC
- Start
- Dec 13, 2022
- Primary completion
- Apr 28, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05488314 · updated Nov 3, 2026